1169 / 2351
5/30/16
16
•
Better outcome for HPV+ patients
•
Not the proper time yet for treatment de-
intensification or change in treatment
strategy!
•
Different trials for HPV+ and HPV- patients
•
Routine p16 staining for oropharyngeal SCC
And in HPV
+
patients?
EHNS-ESTRO H&N course
Florence, June 2016
HPV in H&N cancer
Ang et al, 2010
≈88% at 5y
≈65% at 5y
≈38% at 5y
EHNS-ESTRO H&N course
Florence, June 2016